UBS Bets on Viking’s VK2735 to Stand Out in Crowded Obesity Market with $94 Target
VK2735 shows rapid weight loss in Phase 2, with financing through 2027.
VK2735 shows rapid weight loss in Phase 2, with financing through 2027.
Eli Lilly, Merck, AbbVie, and UnitedHealth rose as markets fell on stronger inflation data, highlighting healthcare’s defensive strength.
Foghorn and Lilly will not advance FHD-909 or their SMARCA2 degrader. Foghorn is cutting about 40% of staff to fund its pipeline into late 2029.
The deal adds HRS-1596 to Novo’s pipeline as Lilly, daily pills and other oral GLP-1s intensify competition in obesity and diabetes.
Eli Lilly CEO Dave Ricks says obesity-drug cash will fund slightly larger buys in sleep, cancer, brain disease, and other underserved science.
California jury found Lilly breached good faith in the 2017 rezpeg deal and awarded Nektar $90 million plus interest. Lilly plans to appeal.